ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,107 | -49.3% | 9,248 | -9.1% | 0.03% | -47.4% |
| Q2 2023 | $96,939 | +44.8% | 10,172 | +67.1% | 0.06% | +54.1% |
| Q1 2023 | $66,968 | -46.3% | 6,088 | -27.7% | 0.04% | -43.1% |
| Q4 2022 | $124,660 | +23.4% | 8,423 | +59.7% | 0.06% | +62.5% |
| Q3 2022 | $101,000 | -9.0% | 5,275 | +0.8% | 0.04% | -2.4% |
| Q2 2022 | $111,000 | -44.5% | 5,232 | -49.5% | 0.04% | -54.4% |
| Q1 2022 | $200,000 | -11.9% | 10,359 | -5.5% | 0.09% | +4.7% |
| Q4 2021 | $227,000 | +30.5% | 10,965 | +50.1% | 0.09% | +11.7% |
| Q3 2021 | $174,000 | -17.1% | 7,304 | -5.0% | 0.08% | -10.5% |
| Q2 2021 | $210,000 | -29.5% | 7,692 | -25.3% | 0.09% | -31.7% |
| Q1 2021 | $298,000 | +4.6% | 10,302 | +1.8% | 0.13% | +6.8% |
| Q4 2020 | $285,000 | -19.5% | 10,117 | -16.3% | 0.12% | -36.6% |
| Q3 2020 | $354,000 | -14.7% | 12,081 | -11.9% | 0.19% | -5.6% |
| Q2 2020 | $415,000 | – | 13,718 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |